GSK announced today that Health Canada has approved Blenrep (belantamab mafodotin for injection) in combination with ...

The combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including ...

However, yesterday GSK announced that the FDA has extended the review period for Blenrep to give the agency time to review ...

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug, Blenrep, as a combination treatment ...

(Alliance News) - GSK PLC on Thursday said its Blenrep blood cancer treatment has been approved in Europe, as it awaits a final decision from the US regulator. The London-based pharmaceutical firm ...

London: GSK plc has announced the extension of the US Food and Drug Administration (FDA) review period for the Biologics ...

European Union approves GSK’s Blenrep combinations to treat relapsed/refractory multiple myeloma: London, UK Saturday, July 26, 2025, 11:00 Hrs [IST] GSK plc announced the appro ...

GSK’s blood cancer drug Blenrep has been reapproved by the EU medicines regulator after it was removed from sale in 2023 because a trial failed to show it was superior to other treatments.

The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...

The new target action date for Blenrep, which GSK is proposing for the second-line treatment of relapsed or refractory multiple myeloma, is Oct. 23.

Blenrep had previously been approved in the U.S., European Union, U.K., and other countries, but GSK pulled it from the market in 2022 after the drug failed in a study meant to confirm its benefit ...